WHO Prequalification of Diagnostics Programme PUBLIC REPORT

Product: Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3 Number: PQDx 0121-043-00

Abstract

Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3 with product codes¹ 9F80-01, 9F80-05 and 2G27-01, manufactured by DiaSorin S.p.A UK Branch, CE marked regulatory version, was accepted for the WHO list of in vitro prequalified diagnostics and was listed on 10 October 2014.

Murex HBsAg Version 3 is an enzyme immunoassay for the detection of hepatitis B surface antigen in human serum or plasma. The assay is intended to screen individual human donors for the presence of hepatitis B surface antigen or as an aid to the diagnosis of HBV infection.

Murex HBsAg Confirmatory Version 3 functions by means of specific antibody neutralization of HBsAg in specimens that are repeatedly reactive in the Murex HBsAg Version 3.

Principle of test procedure:

In Murex HBsAg Version 3, the specimen is pre-incubated in microwells coated with a mixture of mouse monoclonal antibodies specific for different epitopes on the 'a' determinant of HBsAg. Affinity purified goat antibody to HBsAg conjugated to horseradish peroxidase is then added to the specimen in the well. During the two incubation steps any HBsAg present in the specimen is bound to the well in an antibody-antigen-antibodyenzyme complex. In the absence of HBsAg no conjugate will be bound. After washing to remove sample and unbound conjugate, а solution containing 3.3'.5.5'tetramethylbenzidine (TMB) and hydrogen peroxide is added to the wells. Wells which contain HBsAg and hence bound conjugate will develop a purple colour which is converted to orange when the enzyme reaction is terminated with sulphuric acid.

Specimens giving an absorbance equal to or greater than the cut-off value are considered initially reactive in the assay. Such specimens should be re-tested in duplicate. Specimens that are reactive in at least one of the repeat tests are presumed to contain HBsAg and should be confirmed by testing with the Murex HBsAg Confirmatory Version 3 kit (2G27-01) and for other HBV markers.

The test kit contains: Murex HBsAg Version 3; product code 9F80-01 (96 tests) Each test kit contains: 1 plate of 96 coated wells, 1 (16ml) bottle of sample diluent, 1 (2.5ml) bottle of negative control, 1 (2ml) bottle of positive control, 1 (6ml) bottle of conjugate containing HRP labelled goat antibody to HBsAg, 1 bottle (35ml) of substrate diluent containing tri-sodium citrate and hydrogen peroxide, 1 (35ml) bottle of substrate concentrate containing TMB, and 1 (125ml) bottle of wash fluid. *Note: 2M sulphuric acid required as stop solution not included in this test kit configuration, although it can be provided as either code N0164 for the 15 vial pack or code N0165 for the 1 vial pack.*

Murex HBsAg Version 3; product code 9F80-05 (480 tests)

Each test kit contains: 5 plates of 96 coated wells, 1 (16ml) bottle of sample diluent, 1 (2.5ml) bottle of negative control, 1 (2ml) bottle of positive control, 2 (16ml) bottles of conjugate containing HRP labelled goat antibody to HBsAg, 1 bottle (35ml) of substrate diluent containing tri-sodium citrate and hydrogen peroxide, 1 (35ml) bottle of substrate concentrate containing TMB, and 1 (125ml) bottle of wash fluid. *Note: 2M sulphuric acid required as stop solution not included in this test kit configuration, although it can be provided as either code N0164 for the 15 vial pack or code N0165 for the 1 vial pack.*

Murex HBsAg Confirmatory Version 3; product code 2G27-01 (50 tests)

Each kit contains: 1 (1.25mL) bottle of Control Reagent, containing buffer and 1 (1.25mL) bottle of Specific Reagent, containing specific horse antibody to HBsAg. Both bottles contain Proclin[®]300 preservative.

Storage: The test kit should be stored between 2°C and 8°C.

Shelf-life:

12 months for Murex HBsAg Version 3

17 months for Murex HBsAg Confirmatory Version 3.

Summary of prequalification status for Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3

	Ini	Initial acceptance		
	Date	Outcome		
Status on PQ list	10 October 2014	listed		
Dossier assessment	05 August 2014	MR		
Inspection status	12 August 2014	MR		
Laboratory evaluation	12 August 2014	MR		

MR: Meets Requirements NA: Not Applicable Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3 was accepted for the WHO list of prequalified diagnostics on the basis of data submitted and publicly available information.

Background information

DiaSorin S.p.A UK Branch submitted an application for prequalification of Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3. Based on the established prioritization criteria, Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3 was given priority for prequalification.

Product dossier assessment

DiaSorin S.p.A UK Branch submitted a product dossier for Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3 as per the "Instructions for compilation of a product dossier" (PQDx_018 v1). The information submitted in the product dossier was reviewed by WHO staff and external experts (assessors) appointed by WHO in accordance with the internal report on the screening and assessment of a product dossier (PQDx_009 v2). Based on the product dossier screening and assessment findings, a recommendation was made to accept the product dossier for Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3 for prequalification.

Commitments for prequalification:

The manufacturer committed to amend and submit additional documentation on the following issues:

- 1. Additional analytical specificity studies
- 2. Additional evidence supporting traceability of control materials
- 3. Further studies in support of in use stability
- 4. Further studies in support of transport stability

Manufacturing site inspection

A comprehensive inspection was performed at the site of manufacture (Dartford, UK and Saluggia, Italy) of the Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3 test in February 2014 as per the "Information for manufacturers on prequalification inspection procedures for the sites of manufacture of diagnostics" (PQDx_014 v1). The inspection found that the manufacturer had an acceptable quality management system and good manufacturing practices in place that ensured the consistent manufacture of a product of good quality. The manufacturer's responses to the nonconformities found at the time of the inspection were accepted and successfully closed on August 11 2014.

Laboratory evaluation

Murex HBsAg Version 3 (DiaSorin S.p.A UK Branch) was evaluated by WHO in the 1st quarter of 2013 using serum/plasma specimens. From this evaluation, we drew the following conclusions:

Murex HBsAg Version 3 (DiaSorin S.p.A UK Branch) is an enzyme immunoassay for the detection of HBsAg in human serum or plasma. A volume of 75μ l of specimen is needed to perform the assay. This type of assay requires laboratory equipment and cannot be performed in laboratories with limited facilities. Reading of the results must be performed with a spectrophotometer.

In this limited performance evaluation on a panel of 515 specimens, we found an initial sensitivity (95% CI) of 100% (98.2% – 100%) and an initial specificity (95% CI) of 98.4% (96.3% – 99.5%) compared to the reference results. The final sensitivity (95% CI) was 100% (98.2% – 100.0%) and the final specificity (95% CI) was 99.0% (97.2% – 99.8%)) compared to the reference results. Lot to lot variation was in the acceptance range.

For six seroconversion panels, Murex HBsAg Version 3 detected on average 0.5 specimens earlier than the benchmark assay (Monolisa Ag HBs Plus [Bio-Rad]. For the low titer panel, Murex HBsAg Version 3 correctly classified all specimens.

For the 1st International Biological Reference Preparation for Hepatitis B surface antigen NIBSC code 03/262, Murex HBsAg Version 3 detected to 0.13 IU/ml. As a comparison, Hepanostika HBsAg ULTRA detected to 0.13 IU/ml.

In this study, 0.18% of the results were recorded as indeterminate. The invalid rate was 0%.

Labelling

- 1. Labels
- 2. Instructions for use

1. Labels


Murex HBsAg version 3 (9F80-01 /9F80-05)



GE36	is commerciales d'DiaSorin rerali di DiaSorin rerali di DiaSorin	to avism abert for wis 600 ^{en} ⁶ 300 na sort pas de marque ⁶ 300 na sort ante virtante ¹⁰⁰ no sort marcas contral ¹⁰⁰ no sort marcas ¹⁰⁰ no sort ¹⁰⁰	n IDorf 9e ^e xobinos8 Dorf bru ^e xobinos8 ^e niDorf e ^e xobinos8 ^e niDorf y ^e xobinos8				Preservatives, Conservatives, Conservatives, c 0.25% Bronidox ⁶ c 0
05	Ĩ						жп
6	۵۸					d, DA1 5LR Road ROAT 5LR	IshtneO Central
9F80-05	5.C-			3 b302+b321+b338 b580 H318 H313 3	b333+b31 b363 b363 b380 b380 b380 b380 b380 b380 b381 b381 b383 b383 b383 b383 b383 b383)	E C
REF	sebsbivs⊃\ z∎eW	480		£ noi	g Vers	AsaH	Murex
B0-0	Dosage immunoen Enzymimmunoassa Dosaggio immunoe	say for the detection zymatique pour la dét ay zum Nachweis des enzimatico per la rileva	of Hepatitis B Surface tection de l'antigène d Hepatitis-B-Surface- azione dell'antigene d	e Antigen de surface du virus de Antigens li superficie de l virus c	le∎'epatite B	400) We∎s /Cavidade
³ 9F80-05	Enzyme immunoasi Dosage immunoeni Enzymimmunoassa Dosaggio immunoe Enzimoinmunoaná <u>l</u> Ensaio imunoenzim	say for the detection - zymatique pour la dét ay zum Nachweis des enzimatico per la rileva isis para la detección nático para a detecção	of Hepatitis B Surface tection de l'antigène d Hepatitis-B-Surface- azione dell'antigene d del antigeno de supe o do antigénio de sup	a Antigen de surface du virus de Antigens li superficie del virus d rificie de la hepatitis B verfície da hepatite B	lel epatite B	63	01
™ 9F80-0 {	Enzyme immunoas: Dosage immunoan: Enzymimmunoassa Dosaggio immunoe Enzimoinmunoanái Ensaio imunoenzim 1 <u>Coartes</u> Wells 5 x 96 Wells 2 sample De 10	say for the detection a zymatique pour la dét ty zum Nachweis des anzimatico per la rileva isis para la detección dático para a detecção	of Hepatitis B Surface tection de l'antigène d Hepatitis-B-Surface- azione dell'antigene d del antigeno de supe o do antigénio de sup	a Antigen le surface du virus de Antigens li superficie del virus c rficie de la hepatitis B erfície da hepatite B	e∎'epatite B		
	Enzyme immunoas Dosage immunoen Enzymimmunoassa Dosaggio immunoe Enzimoinmunoanáli Ensaio imunoenzim	say for the detection - zymatique pour la dét y zum Nachweis des enzimatico per la rilev- isis para la detección rático para a detecção Coated Weis	of Hepatitis B Surface lection de l'antigène d Hepatitis-B-Surface- azione dell'antigene d del antigeno de supe o do antigénio de sup (Cupules recouvertes	a Antigen ie surface du virus de Antigens li superficie del virus d rficie de la hepatitis B erfície da hepatite B Beschichtete Vertiefungen	Pozzeti rivestiti	es Pocijos recubientos	Paços revestidos
	Enzyme immunoas: Dosage immunoen: Enzymimmunoassa Dosaggio immunoen Enzimoinmunoanáli Ensaio imunoenzim 1 <u>coarteo wells</u> 5 x 96 Wells 2 <u>samrie (B.</u> 16 16 ml 3 <u>coarteo (M. 16</u> 16)	say for the detection - zymatique pour la dét ty zum Nachweis des enzimatico per la rilev; isis para la detección tático para a detección coated Weis Sample Dilent y Negative Control	of Hepatitis B Surface tection de l'antigène d Hepatitis-B-Surface- azione dell'antigene d del antigeno de supe o do antigénio de sup (Cupules recovertes Diant pour échartilions y Contéle-négatif	a Antigen de surface du virus de Antigens li superficie del virus d rficie de la hepatitis B erfície da hepatite B Beschichtele Vertiefungen Probenverdünnungsmittel v Negative Kontre li e	Pezzeti rivestiti Diluente del campione y Contrello negativo	es Pocillos recubientos Diluyente de muestra y Control negativo	₽0ços revestidos Di∎ente da amostra ψ Controlo negativo
	Enzyme immunoas: Dosage immunoana Enzymimmunoasa Dosaggio immunoen Enzimoinmunoanali Ensaio imunoenzim 1 <u>coartes wells</u> 5 x 60 Wells 2 <u>saares</u> b 16 ml 3 <u>coartes wells</u> 3 <u>coartes to Wells</u> 4 <u>coartes to A</u>	say for the detection - zymatique pour la dét ty zum Nachweis des enzimatico per la rileva isis para la detección nático para a detección nático para a detección coated Wells Sample Dilent y Negative Control (humar) † Positive Control	of Hepatitis B Surface lection de l'antigène d Hepatitis-B-Surface- azione de l'antigene d del antigeno de supe o do antigénio de sup Cupules recorvertes Duart pour échartilens y Contrôle négatif (rumain) † Contrôle positif	a Antigen de surface du virus de Antigens li superficie del virus d rificie de la hepatitis B erfície da hepatite B Beschichtete Vertiefungen Probenverdünnungsmittel v Negative Kontrolle (turman) †	Pozzeti rivesti Dituente de campione y Controllo negativo (umano) T Controllo positivo	Pocijos recubientos Delayente de muestra y Control negativo (humano) † Control positivo	Poços revestidos Di∎ente da amostra ↓ Controlo negativo (humano) † Controlo positivo
	Enzyme immunoas: Dosage immunoas: Enzymimmunoas: Dosaggio immunoen Enzimoimmunoanáji Ensaio imunoenzim 1 <u>Coares wells</u> 2 <u>samele</u> 2 <u>samele</u> 3 <u>conrect</u> 4 <u>conrect</u> 4 <u>conrect</u>	say for the detection - zymatique pour la ciét ty zum Nachweis des enzimatico per la rilevi isis para la detección tático para a detección coated Weije Samele Dilent y Negative Centrel (humari) †	of Hepatitis B Surface lection de l'antigène d Hepatitis-B-Surface- azione dell'antigene d del antigene de supe o do antigénio de sup (Cupulos recovertes Dilart pour échartilions y Contrôle négatif (rumain) †	 Antigen Antigens auperficie del virus de rificie de la hepatitis B cerficie da hepatite B cerficie da hepatite B Beschichtete Vertiefungen Probenverdünnungsmittel v Negative Kontrolle (human) † 	Pozzeti rivestili Diserte del campione y Controllo negativo (umano) †	Pocijos recubientos Diluyente de muestra y Control negativo (humano) † Control positivo (humano) †	Poços revestidos Disente da amostra y Controlo negativo (numano) † Controlo positivo (humano) †
	Enzyme immunoas: Dosage immunoen: Enzymimmunoas: Dosaggio immunoen Enzimoinmunoanáli Ensaio imunoenzim 1 coartes wells 5 x 96 Wells 2 samue b 16 mi 3 contract A 2.5 mi 4 contract A 2 mi 5 consubare M 5 consubare M	say for the detection - zymatique pour la dét ty zum Nachweis des enzimatico per la rilev; isis para la detección tático para a detección coated Weis Sample Dillent V Negative Centrel (humar) † Positive Centrel (humar) † Conjugale v Substrale Dillent	of Hepatitis B Surface tection de l'antigène d Hepatitis-B-Surface- azione dell'antigene d del antigene de supe o do antigénio de sup Cupules recovertes Dilart paur échartilions y Contrôle négatif (rumain) † Contrôle positif (rumain) †	a Antigen de surface du virus de Antigens li superficie del virus de rficie de la hepatitis B erfície da hepatite B Beschichteia Vertiefungen Probenverdünnungsmittel v Negative Kontrolle (human) † Konjugat v Substratverdünnungsmittel	Pezzeti rivestili Diluerte del campione y Controllo negativo (umano) † Controllo positivo (umano) †	ess Pocijos recubientos Diluyente de muestra y Control negativo (tumano) † Control positivo (tumano) † Conjugado y Diluyente de sustrato	Poços revestidos Diluente da amostra y Contrelo negativo (humano) † Controlo positivo (numano) † Conjugado y Diluente do substrato

Murex HBsAg Version 3 (9F80-01/-05) GE34 Murex HBsAg Version 3 Murex HBsAg GE34/36 DiaSorin 6 ml DiaSorin Version 3 96 Wells/ CONJUGATE LOT Cavidades 1 H317 P280 P363 P333+P313 1/-8℃ IVD LOT COATED **WELLS** 2°C-1 3LA3DS34D 8 ~8°C IVD Murex HBsAg Version 3 GE36 2°C DiaSorin 16 ml 4LA2DS34C CONJUGATE LOT 1 1 H317 P280 P363 P333+P313 IVD 2°C-4LA3DS36D 400E 500E, GE41/42, GE80/81, GE94/95, GE34/36 2.5 ml DiaSorin CONTROL -Murex HBsAg GE34/36 Version 3 2 ml 5 DiaSorin -8°C IVD 2°C-3L10DS94L CONTROL + 1∕-8°C IVD 2°C 2LA5DS34F 35 ml DiaSorin Murex HBsAg GE34/36 DiaSorin Version 3 16 ml SUBSTRATE CONC LOT SAMPLE DIL LOT 1 H317 P280 P363 P333+P313 N~8℃ 3 H319 P264 P280 P305+P -8°C 2°C-IVD 1LA3DS34D 2°C-IVD 1DA81TMBJ **Murex HBsAg Version 3 GE34** 2 REF 9F80-01 Kit LOT 96 Wells 96 Cavidades 1 5 6 35 ml 234 1 2014 - 09 78 DiaSorin DS34CAR10 SUBSTRATE DIL -8°C IVD 2°C-1 1DA6SUBDG Murex HBsAg Version 3 **GE36** 2 REF 9F80-05 Kit LOT 480 Wells 480 Cavidades REF 6F83 125 ml→2.5 L 1 5 DiaSorin 234 6 (20x conc) 1 2014-09 7 8 WASH FLUID LOT DS36CAR11 8 Glycine/Borate CE [∕~ 8°C IVD S.p.A. UK Branch 2°Ci EUH210 1DA9125MG

Murex HBsAg Confirmatory version 3



Murex HBsAg Confirmatory Version 3 (2G27-01)

DiaSorin DiaSorin CONTROL REAGE	and the second	DiaSorin	Con		ry Version : REAGEN	1.20
1 H317 P280 P363 P333+P313 2°C	D123456 2014-07 1LA4DS37D	1 1 + H317 P280 P363 P333+0		2°C-	8°C LOT	2LA4DS3
		100	_	_		
	GE37					
Version 3	REF 2G27-0	6 17				
Murex HBsAg Confirmatory Version 3 LOT 2014 Kit	REF 2G27-0 50 Tests	6 17				
Version 3 LOT	REF 2G27-0 50 Tests	s				

en

2. Instructions for use



The Diagnostic Specialist

REF 9F80-01 / 05 GE34/36

Revised September, 2014

Murex HBsAg Version 3

Enzyme immunoassay for the detection of hepatitis B surface antigen in human serum or plasma


The assay is intended to screen individual human donors for the presence of hepatitis B surface antigen or as an aid to the diagnosis of HBV infection.


Customer Service

For additional product information, please contact your local customer service organization.

This instructions for use must be read carefully prior to use. The instructions for use must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions for use.

IVD





INTENDED USE

Murex HBsAg Version 3 is a rapid and sensitive enzyme immunoassay for the detection of hepatitis B surface antigen in human serum or plasma. The assay is intended to screen individual human donors for the presence of hepatitis B surface antigen or as an aid to the diagnosis of HBV infection.

SUMMARY AND EXPLANATION OF THE TEST

The causative agent of serum hepatitis is hepatitis B virus (HBV) which is an enveloped DNA virus. During infection, HBV produces an excess of hepatitis B surface antigen (HBsAg), also known as Australia antigen, which can be detected in the blood of infected individuals. HBsAg is the first serological marker after infection with HBV appearing one to ten weeks after exposure and two to eight weeks before the onset of hepatitis^{1,2}. HBsAg persists during this acute phase and clears late in the convalescence period. Failure to clear HBsAg within sk months indicates a chronic HBsAg carrier state. Blood from individuals in the acute or chronic state is potentially infectious to recipients and should not be transfused. Consequently, potentially infectious samples of serum, EDTA plasma or citrate plasma can be identified.

PRINCIPLE OF THE PROCEDURE

In Murex HBsAg Version 3, the sample is pre-incubated in microwells coated with a mixture of mouse monoclonals specific for different epitopes on the 'a' determinant of HBsAg. Affinity purified goat antibody to HBsAg conjugated to horseradish peroxidase is then added to the sample in the well. During the two incubation steps any HBsAg present in the sample is bound to the well in an antibody-antigen-antibody-enzyme complex. In the absence of HBsAg no conjugate will be bound. After washing to remove sample and unbound Conjugate, a solution containing 3,3', 5,5'-tetramethylbenzidine (TMB) and hydrogen peroxide is added to the wells. Wells which contain HBsAg and hence bound Conjugate will develop a purple colour which is converted to orange when the enzyme reaction is terminated with sulphuric acid.

REAGENTS

DESCRIPTION, PREPARATION FOR USE AND RECOMMENDED STORAGE CONDITIONS See also Warnings and Precautions.

∬ **~8°C**

2°C-

All components must be stored at 2 to 8°C, unless otherwise stated, under which condition they will retain activity until the expiry date of the kit.

2. Sample Diluent

COATED WELLS 1. Coated Wells

One plate (9F80-01) or five plates (9F80-05) of 96 wells coated with mouse monoclonal antibody to HBsAg.

Allow the wells to reach room temperature (18 to 30°C) before removal from the bag. Place unused wells in the sealable storage bag provided and return to 2 to 8°C.

SAMPLE DIL

One bottle containing 16 ml of green/brown buffer containing detergents and proteins of goat and bovine origin. Mix by inversion before use. Contains 0.05% ProClin® 300 preservative.

CONTROL - 3. Negative Control

One bottle containing 2.5 ml of normal human serum. The serum is diluted in a buffer containing protein of bovine origin. Contains 0.05% Bronidox® preservative.

CONTROL + 1. Positive Control

One bottle containing 2 ml of inactivated human serum. The serum is diluted in a buffer containing protein of bovine origin. Contains 0.05% Bronidox® preservative.



SUBSTRATE DL

5. Conjugate

One bottle containing 6 ml (9F80-01) or two bottles each containing 16 ml (9F80-05) of horseradish-peroxidase labelled goat antibody to HBsAg in a red buffer containing proteins of bovine and goat origin. Mix by inversion before use. Contains 0.05% ProClin® 300 preservative.

6. Substrate Diluent

One bottle containing 35 ml of a colourless solution of tri-sodium citrate and hydrogen peroxide.

SUBSTRATE CONC 7. Substrate Concentrate

One bottle containing 35 ml of 3,3',5,5'-

One bottle containing 35 mi of 3,3',5,5'tetramethylbenzidine (TMB) and stabilisers in a pink solution.

Substrate Solution

To prepare the Substrate Solution add a volume of colourless Substrate Diluent to an equal volume of pink Substrate Concentrate in either a clean glass or plastic vessel. It is important that this order of addition is followed and that any pipettes and glassware used to prepare Substrate Solution are clean.

Alternatively, the Substrate Solution may be made by pouring the entire contents of the bottle of Substrate Diluent into the bottle of Substrate Concentrate. One bottle of Substrate Solution provides sufficient reagent for at least five plates - see **Table 1**:



Vo	Volume of Substrate Concentrate and Substrate Diluent Required													
Nur	nber	of V	/ells								No	of P	lates	
8	16	24	32	40	48	56	64	72	80	96	1	2	3	4
Subs	Substrate Concentrate (ml)													
0.5	1.0	2.0	2.5	2.5	3.0	3.5	4.0	4.5	4.5	6.0	6	12	18	22
Subs	Substrate Diluent (ml)													
0.5	1.0	2.0	2.5	2.5	3.0	3.5	4.0	4.5	4.5	6.0	6	12	18	22

Table 1

Additional reagent may be required for use with automated systems. Keep away from sunlight. The Substrate Solution should be pink; if it is purple before being used, it should be discarded and fresh Substrate Solution prepared.

The prepared Substrate Solution from this kit may be used interchangeably with that from all other Murex kits which use pink coloured Substrate Concentrate. Ensure that the Substrate Solution is prepared from Substrate Diluent and Substrate Concentrate provided together.

The prepared Substrate Solution is stable refrigerated (2 to 8°C) or at 15 to 25°C for up to two days but must be discarded if crystals have formed.

WASH FLUID

8. Wash Fluid

One bottle containing 125 ml of 20 times working strength Glycine/Borate Wash Fluid. Contains 0.2% Bronidox® preservative.

Add one volume of Wash Fluid Concentrate to 19 volumes of distilled or deionised water to give the required volume or dilute the entire contents of one bottle of Wash Fluid to a final volume of 2500 ml. Crystals may be observed in the Wash Fluid Concentrate but these crystals will dissolve when the Wash Fluid is diluted to working strength. When diluted, the Wash Fluid contains 0.01% Bronidox® preservative

The Wash Fluid from this kit may be used interchangeably with the Glycine/Borate Wash Fluid from any other Murex kit.

Store the working strength Wash Fluid at 18 to 30°C in a closed vessel under which conditions it will retain activity for one month. NOTE: The Wash Fluid may develop a yellow colour on storage. This will have no effect on the performance of the assay providing the Wash Fluid is fully aspirated from the wells.

NOTE: Although the Substrate Solution and Wash Fluid are interchangeable, they must not be used beyond the expiry date printed on the component labels.

WARNINGS AND PRECAUTIONS

IVD

The reagents are for in vitro diagnostic use only.

For professional use only.

Please refer to the manufacturer's safety data sheet and the product labelling for information on potentially hazardous components. HEALTH AND SAFETY INFORMATION



CAUTION: This kit contains components of human origin. The human sera used for manufacture have been screened and found reactive or non-reactive for analytes as shown in Table 2 below.

Table 2

Component	Reactive for	Non-reactive for
Negative Control	N/A	HBsAg, and antibodies to HIV-1 and 2, HCV and HTLV I + II
Positive Control	HBsAg	Antibodies to HIV-1 and HIV-2, and HCV

All reactive serum used has been inactivated prior to use in reagent preparation. However, all material of human origin should be considered as potentially infectious and it is recommended that this kit and test specimens be handled using established good laboratory practice.

Pursuant to EC Regulation 1272/2008 (CLP) hazardous reagents are classified and labeled as follows:

LE DIL , CONJUGATE 1 H317 cause an allergic skin reaction r protective gloves/protective e protection/face protection. n contaminated olothing before reuse. 3 If skin irritation or rash occurs: Get vice / attention. hass of: 5-chloro-2-methyl-4- -3-one [EC no. 247-500-7] and
cause an allergic skin reaction r protective gloves/protective e protection/face protection, n contaminated clothing before reuse, 3 If skin irritation or rash occurs: Get vice /attention, nass of: 5-chloro-2-methyl-4-
protective gloves/protective e protection/face protection, n contaminated clothing before reuse. 3 If skin irritation or rash occurs: Get vice /attention. hass of: 5-chloro-2-methyl-4-
protective gloves/protective e protection/face protection. n contaminated clothing before reuse. 3 If skin irritation or rash occurs: Get vice /attention. hass of: 5-chloro-2-methyl-4-
protective gloves/protective e protection/face protection, n contaminated clothing before reuse. 3 If skin irritation or rash occurs: Get vice /attention. hass of: 5-chloro-2-methyl-4-
e protection/face protection. contaminated clothing before reuse. If skin irritation or rash occurs: Get vice /attention. hass of: 5-chloro-2-methyl-4-
H -isothiazol-3-one [EC no. 220-).
TE CONC
H319
es serious eye irritation
hands thoroughly after handling
I

For additional information see Safety Data Sheets available on www. diasorin.com

- Potentially contaminated materials should be disposed of safely according to local requirement.
- 2. Spillage of potentially infectious material should be removed immediately with absorbent paper tissue and the contaminated area swabbed with, for example, 1.0% sodium hypochlorite before work is continued³. Sodium hypochlorite should not be used on acid containing spills unless the spill area is first wiped dry. Materials used to clean spills, including gloves, should be disposed of as potentially biohazardous waste. Do not autoclave materials containing sodium hypochlorite.
- Neutralised acids and other liquid waste should be decontaminated by adding a sufficient volume of sodium hypochlorite to obtain a final concentration of at least 1.0%. A 30 minute exposure to 1.0% sodium hypochlorite may be necessary to ensure effective decontamination.
- Do not pipette by mouth. Wear disposable gloves and eye protection while handling specimens and performing the assay. Wash hands thoroughly when finished.
- The following reagents contain low concentrations of harmful substances.
 - a) The Conjugate and Sample Diluent contain detergents.
- 6. Sulphuric acid required for the Stop Solution and hydrochloric acid used for washing glassware are corrosive and should be handled with appropriate care. If either come into contact with the skin or eyes, wash thoroughly with water.
- If any of the reagents come into contact with the skin or eyes wash the area extensively with water.

ANALYTICAL PRECAUTIONS

- Do not use the reagents beyond the stated expiry date. Microbiological contamination of reagents must be avoided as this may reduce the life of the product and cause erroneous results.
- Do not modify the **Test Procedure** or substitute reagents from other manufacturers or other lots unless the reagent is stipulated as interchangeable. Do not reduce any of the recommended incubation times.
- Allow all reagents and samples to come to 18 to 30°C before use. Immediately after use return all reagents to the recommended storage temperature.
- Any glassware to be used with the reagents should be thoroughly washed with 2M hydrochloric acid and then rinsed with distilled water or high quality deionised water.
- Avoid the use of self-defrosting freezers for the storage of reagents and samples.
- Do not expose reagents to strong light or hypochlorite fumes during storage or during incubation steps.
- 7. Do not allow wells to become dry during the assay procedure.
- Do not cross-contaminate reagents. Dedicate a pipette for use with the Substrate Solution of Murex assays. A pipette should also be dedicated for use with the Conjugate.
- Do not touch or splash the rim of the well with Conjugate. Do not blow out from micropipettes; reverse pipetting is recommended wherever possible.
- 10. Ensure that the bottom of the plate is clean and dry and that no bubbles are present on the surface of the liquid before reading the plate.
- Do not contaminate microwells with the dust from disposable gloves.
- 12. When using fully automated microplate processors
 - i) It is not necessary to use plate lids and to tap dry the wells.
 ii) Do not allow system fluids from fully automated microplate
 - processors to contaminate samples or reagents. iii) The possibility of cross contamination between assays needs to be
 - excluded when validating assays on fully automated processors
- Ensure the assay is run within the temperature limits defined in the assay protocol.
- 14. Do not use CO2 incubators.
- Do not store the Stop Solution in a shallow dish or return it to a stock bottle after use.
- The possibility of cross contamination between assays needs to be excluded when validating assay protocols on instrumentation.

SPECIMEN COLLECTION, TRANSPORT AND STORAGE SPECIMEN COLLECTION

Serum, EDTA plasma or citrate plasma samples may be used. Blood collected by venepuncture should be allowed to clot naturally. Ensure that the serum samples are fully clotted. Remove any visible particulate matter from the sample by centrifugation. If samples are prepared using liquid anticoagulants e.g. citrate plasma, the dilution effect should be considered.

SPECIMEN TRANSPORT AND STORAGE

Store samples at 2 to 8°C. Samples not required for assay within 72 hours should be removed from the clot or cell pellet and stored frozen (-15°C or colder). Avoid multiple freeze-thaw cycles. After thawing, ensure samples are thoroughly mixed before testing.

PROCEDURE

- MATERIALS REQUIRED BUT NOT PROVIDED
- Stop Solution (0.5M to 2M Sulphuric Acid). e.g. add between 3 ml (for 0.5M) and 11 ml (for 2.0M) of analytical grade concentrated sulphuric acid (18.0M) to about 80 ml of distilled or deionised water and then make up to 100 ml with more water. Alternatively, the following reagent can be used; 1N Sulphuric Acid (Code N0164, 15 vial pack and N0165, 1 vial pack).
- Freshly distilled or high quality deionised water is required for dilution of Wash Fluid, for preparation of the Stop Solution and for use in conjunction with automated washers.
- Micropipettes and Multichannel micropipettes of appropriate volume.
- Incubator capable of maintaining the temperature limits defined in the assay protocol.
- Moulded Heating Block (Code 5F09-02). For use in laboratory incubators. The moulded heating block should ideally be kept in the incubator used. If this is not possible it must be placed in the incubator at least four hours before beginning the assay.

6. Instrumentation

- a) Automated microplate strip washer.
- b) Microplate reader.
- or
- Fully automated microplate processor.
- All instruments must be validated before use.

Please contact your representative for details of recommended systems, software protocols for instrumentation and validation procedures.

- 7. Disposable Reagent Troughs. (Code 5F24-01).
- Sodium hypochlorite for decontamination. (Refer to Health and Safety Information).

9. Sodium hydroxide solution (0.1M) (For instrument decontamination). TEST PROCEDURE

Please read 'Analytical Precautions' carefully before performing the test.

Addition of the various components of the assay to the wells may be confirmed visually by examining the plate for the following colours:

Sample Diluent is green/brown in colour. On addition of the Sample or Control the colour will change to blue/green. The colour change will vary from sample to sample but some change should always be visible.

Conjugate is red in colour.

Substrate Solution is initially pink with any reactive wells becoming purple. On addition of Stop Solution the purple colour of the reactives will change to orange, whilst the negatives remain pink.

The addition of sample or reagent can be confirmed using a microplate reader as follows: Sample Diluent plus Sample read at 570 or 620 nm with a reference at 690 nm, Conjugate at 490 nm with a reference at 690 nm, Substrate Solution at 490 nm (no reference).

SEMI AUT	OMATED PROCESSING	
Step 1	Prepare Substrate Solution and Wash Fluid.	
Step 2	Use only the number of wells required for the test.	
Step 3	Add 25 µl of Sample Diluent to each well.	25 µl
Step 4	Add 75 μ l of Samples or Controls to the wells.	75 µl
	To each plate add 75 µl of the Negative Control to wells A1 and B1 and 75 µl of Positive Control into well C1.	
	Add the Controls to the designated wells afer dispensing the samples.	
Step 5	Cover the plate with a lid and incubate for 60 minutes at 37°C ±1°C.	60 mins
Step 6	Add 50 µl of Conjugate to each well.	50 µl
Step 7	Shake the plate using a plate shaker for 10 seconds or manually agitate by gently tapping the sides for 10 seconds.	10 secs
Step 8	Cover the plate with the lid and incubate for 30 minutes at 37°C ±1°C.	30 mins
Step 9	At the end of the incubation time wash the plate 5 times as described under Wash Procedures . After washing is completed invert the plate and tap out any residual Wash Fluid onto absorbent paper.	5 washes
Step 10	Immediately after washing the plate, add 100 µl of Substrate Solution to each well.	100 µl
Step 11	Cover the plate with a lid and incubate for 30 minutes at 37°C ±1°C while colour develops.	30 mins
	A purple colour should develop in wells containing reactive samples.	
Step 12	Add 50 µl of Stop Solution to each well.	50 µl
Step 13	Within 15 minutes read the absorbance of each well at 450 nm using 620 nm to 690 nm as the reference wavelength if available.	A _{450/Ref}
	Blank the instrument on air (no plate in the carriage).	

WASH PROCEDURES

Protocols for recommended washers and procedures for verifying washers and analysers can be obtained from your representative. The following protocol is recommended:

Protocol for automated microplate stripwasher a)

Perform 5 wash cycles using working strength Wash Fluid. Ensure, where possible, that:

- (i) Flow-through washing with a fill volume of 500 $\mu\text{l/well}$ is used with instrumentation supplied by DiaSorin. When using other instrumentation for which this is not possible, ensure that the well is completely filled.
- (ii) The dispense height is set to completely fill the well with a slight positive meniscus, without causing an overflow.
- (iii) The time taken to complete one aspirate/wash/soak cycle is approximately 30 seconds.
- (iv) Ensure that no liquid is left in the well (by use of a double aspirate step in the final cycle where possible).
- (v) After washing is completed, invert the plate and tap out any residual Wash Fluid onto absorbent paper

NOTE: Do not allow the wells to become dry during the assay procedure.

Washers must be rinsed with distilled water at the end of the test to avoid blockage and corrosion.

FULLY AUTOMATED MICROPLATE PROCESSORS.

Contact your representative for details of currently available validated protocols. For instrumentation without established validated protocols, the following guidelines are recommended:

- 1. Do not programme times shorter than specified in the procedure.
- 2. For each incubation at 37°C, programmed times may be increased by up to 20%.
- 3. Wells containing Sample Diluent may be left for up to 60 minutes at 18 to 30°C prior to addition of sample and controls and for up to 60 minutes after the addition of sample and controls before starting step 5.
- 4. Ensure all 'Analytical Precautions' are followed. Protocols written following these guidelines must be fully validated prior to use according to local procedures.

RESULTS

CALCULATION OF RESULTS

Each plate must be considered separately when calculating and interpreting results of the assay.

Approved software may be used for calculation and interpretation of results.

Negative Control

Calculate the mean absorbance of the replicates of the Negative Control.

If one of the Negative Control wells has an absorbance more than 0.03 above the other discard the higher value.

Cut-off Value

Calculate the Cut-off Value by adding 0.05 to the mean of the Negative Control replicates.

Example

Negative Control absorbance:	well 1	-	0.071, well 2	-	0.075
Mean Negative Control		-	(0.071 + 0.075)/2	-	0.073
Cut-off Value		-	0.073 + 0.05	-	0.123

QUALITY CONTROL

Results of an assay are valid if the following criteria for the controls are met: Negative Control

The mean $A_{450|\text{Ref}}$ of the Negative Control is less than 0.15 or the mean A_{450} of the Negative Control is less than 0.2. Positive Control

The A_{450/Ref} or A_{450} of the Positive Control is more than 0.8 above the mean $A_{450/Ref}$ or A_{450} of the Negative Control.

Assays which do not meet these criteria should be repeated.

In the unlikely event of the results repeatedly failing to meet either the Quality Control criteria or the expected performance of the test, please contact your representative.

INTERPRETATION OF RESULTS

Non Reactive Results

Samples giving an absorbance less than the Cut-off Value are considered non-reactive in Murex HBsAg Version 3.

Reactive Result

Samples giving an absorbance equal to or greater than the Cut-off Value are considered initially reactive in the assay (see Limitations of the Procedure). Such samples should be retested in duplicate using the original sample source. Samples that are reactive in at least one of the re-tests are presumed to contain HBsAg and should be confirmed by using the Murex HBsAg Confirmatory Version 3 kit (2G27-01) and tests for other HBV markers. Samples that are non-reactive in both wells on retest should be considered non-reactive.

SPECIFIC PERFORMANCE CHARACTERISTICS

The performance of Murex HBsAg Version 3 has been determined by testing samples from random blood donors, patients with acute and chronic hepatitis B infection, patients with mutant forms of hepatitis B infection and patients with diseases unrelated to hepatitis B infection.

In addition, its performance against the French A.F.S.S.A.P.S. panels and other commercially available seroconversion samples has been evaluated.

1. Donor Samples

The Murex HBsAg assay demonstrated a specificity of \geq 99.5% in a study where a total of 12330 routine donor samples were screened with Murex HBsAg Version 3. In the study, 0.18% (22/12330) of samples were initially reactive and 0.03% (4/12330) were repeatedly reactive. None of the repeatedly reactive samples with Murex HBsAg version 3 and the alternative assays were confirmed as positive for the presence of hepatitis B surface antigen.

The specificity of Murex HBsAg Version 3 on presumed negative samples from donors is estimated to be 99.97% (12326/12330) with a 95% confidence interval of 99.92% (12320/12330) to 99.99% (12329/12330) by the binomial distribution.*

2. Clinical Samples

Samples from patients at various stages of hepatitis B infection and patients with conditions unrelated to hepatitis B were tested in three regional virus reference laboratories and at DiaSorin.

A total of 630 samples from patients suffering from acute and chronic hepatitis B infection were tested with Murex HBsAg version 3. All 630 samples were confirmed with an alternative immunoassay for HBsAg and found to be positive in both Assays.

A further six samples from patients infected with mutant forms of hepatitis B infection, confirmed by DNA sequencing, were also tested with Murex HBsAg version 3 and were all detected successfully.

In addition 998 potentially cross-reactive samples from patients with conditions unrelated to hepatitis B infection, including other acute viral infections, antenatal, lipaemic, icteric and haemolysed samples, were tested with Murex HBsAg Version 3. A total of 996 of these samples were non-reactive with Murex HBsAg Version 3. Of the two repeatedly reactive samples, one was false reactive and showed no other hepatitis markers, the remaining sample was anti-HBc positive.

3. Seroconversion Panels

A total of 22 commercially available HBV seroconversion panels were tested with Murex HBsAg Version 3. Comparison with two other commercially available microplate based immunoassays for the detection of hepatitis B surface antigen showed that Murex HBsAg Version 3 detected HBsAg six bleeds earlier in one panel, four bleeds earlier in one panel, two bleeds earlier in one panel, one bleed earlier in four panels and at the same bleed in the remaining 15 panels.

4. Assay Reproducibility

Ten replicates of each of five samples were tested on ten separate test occasions with two separate batches to ascertain the reproducibility of Murex HBsAg Version 3. The results of the study are summarised in Table 3 and Table 4.

*Representative performance data are shown: results obtained at individual laboratories and with different populations may vary.

Table 3

Murex	Murex HBsAg Version 3 - Assay Reproducibility (Kit 1)									
Specimen	Number of Assays	Mean Absorbance/ Cut-off Value	Intra-assay %CV	Inter-assay %CV						
1	10	3.36	7.6	9.2						
2	10	1.29	8.2	9.5						
3	10	4.44	10.1	11.5						
4	10	0.68	9.3	10.8						
5	10	0.25	11.0	12.9						

Table 4

IVIU	Murex HbsAg Version 3 - Assay Reproducibility (Kit 2)									
Specimen	Number of Assays	Mean Absorbance/ Cut-Off Value	Intra-assay %CV	Inter-assay %CV						
1	10	3.19	6.8	7.9						
2	10	1.19	7.3	9.1						
3	10	3.73	7.7	8.5						
4	10	0.55	9.2	12.6						
5	10	0.18	7.5	8.3						


LIMITATIONS OF THE PROCEDURE

- 1. The **Test Procedure** and **Interpretation of Results** must be followed.
- This test has only been evaluated for use with individual (unpooled) serum, EDTA plasma, or citrate plasma samples.
- A negative result with an antigen detection test does not preclude the possibility of infection.
- . Non-repeatable reactive results may be obtained with any EIA procedure.
- The most common sources of error are:
- a) Imprecise delivery of Sample, Conjugate or Substrate into the wells.
- b) Contamination of Substrate with Conjugate.
- c) Contamination with conjugates from other assays
- d) Blocked or partially blocked washer probes.
- Insufficient aspiration leaving a small volume of Wash Fluid in the wells.
- f) Failure to ensure that the bottom surface of the wells is clean and dry, and that no air bubbles are present on the surface of the liquid in the wells before a plate is read.
- g) Failure to read at the correct wavelength or use of an incorrect reference wavelength.
- The use of highly haemolysed samples, incompletely clotted sera, plasma samples containing fibrin or samples with microbial contamination may give rise to erroneous results.
- This test has not been evaluated for use with samples from cadavers.

BIBLIOGRAPHY

- Krugman, S. and Giles, J.P. (1973). Viral hepatitis, type B (MS-2-Strain). Further observations on natural history and prevention. *N. Engl. J. Med.*, 288, 755.
- Krugman, S., Overby, L.R. et al., (1979). Viral hepatitis, type B. Studies on natural history and prevention re-examined. N. Engl. J. Med., 300, 101.
- Centres for Disease Control. (1985). Recommendations for preventing transmission of infection with human T-lymphotropic virus type III / lymphadenopathy-associated virus in the workplace. MMWR, 34, No. 45, 681.

Bronidox® and ProClin® are not trade marks of DiaSorin.





D07DS34GB September, 2014

Instruction for use for Murex HBsAg Confirmatory version 3

DiaSorin

The Diagnostic Specialist

en

REF 2G27-01 GE37

Revised September, 2014

Murex HBsAg Confirmatory Version 3

For the confirmation of the presence of hepatitis B surface antigen in serum and plasma samples.

Customer Service

For additional product information, please contact your local customer service organization.

This instructions for use must be read carefully prior to use. The instructions for use must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions for use.



	Key to symbols used									
REF	List Number	IVD	In Vitro Diagnostic Medical Device							
LOT	Lot Number	2°C-	Store at 2-8'C							
\square	Expiration Date	\triangle	CAUTION: Consult accompanying documents							
	Manufacturer	Ĩ	Consult instructions for use							

See **REAGENTS** section for a full explanation of symbols used in reagent component naming.

INTENDED USE

Murex HBsAg Confirmatory Version 3 (2G27) is used to confirm the presence of hepatitis B surface antigen (HBsAg) in serum or plasma samples found to be reactive in the Murex HBsAg Version 3 (9F80) assay.

SUMMARY AND EXPLANATION OF THE TEST

Murex HBsAg Confirmatory functions by means of specific antibody neutralisation of HBsAg in samples that are repeatably reactive in the Murex HBsAg (9F80) assay. In contrast to the goat and mouse antibodies used in the HBsAg (9F80) assay, the specific antibody used in the confirmatory reagent is derived from horse, this precaution minimises the risk of confirming false positive samples containing anti-species antibodies.

PRINCIPLE OF THE PROCEDURE

For each test sample two assay wells are assigned. The Murex HBsAg assay is run according to the usual procedure except that the Sample Diluent is substituted with Control Reagent in the control well and Specific Reagent in the specific well. During the first incubation the horse anti-HBs in the Specific Reagent will compete with the mouse antibodies immobilised on the well for any HBsAg present in the sample and will reduce the amount of HBsAg binding to the well; in the control well there is no competition and the HBsAg will bind normally. Conjugate is then added and the assay completed in the normal way. In samples containing HBsAg there will be a significant difference between the A450 generated in control and specific wells, if the inhibition in the specific well exceeds 50%, the sample is considered to be confirmed reactive.

REAGENTS

DESCRIPTION, PREPARATION FOR USE AND RECOMMENDED STORAGE CONDITIONS See also Warnings and Precautions.

∫,**~8°C**

2°C-/

All 2G27 components must be stored at 2 to 8°C, under which condition they will retain activity until the expiry date of the kit.

1. Control Reagent CONTROL REAGENT One bottle containing 1.25 ml of a yellow coloured buffer containing detergents and material of horse, goat, human and bovine origin. Contains 0.038% ProClin® 300 preservative. 2. Specific Reagent

SPECIFIC REAGENT

One bottle containing 1.25 ml of specific horse antibody to HBsAg in a red coloured buffer containing detergents and material of horse, goat, human and bovine origin. Contains 0.038% ProClin® 300 preservative.

WARNINGS AND PRECAUTIONS

IVD

The reagents are for in vitro diagnostic use only.

For professional use only.

Please refer to the manufacturer's safety data sheet and the product labelling for information on potentially hazardous components.

HEALTH AND SAFETY INFORMATION

CAUTION: This kit contains components of human origin.

The human sera used for manufacture have been screened and found reactive or non-reactive for analytes as shown in Table 1 below:

Table 1

Component	Reactive for	Non-reactive for
Control Reagent	N/A	HBsAg, anti-HCV and anti- HIV-1/HIV-2
Specific Reagent	N/A	HBsAg, anti HCV and anti- HIV-1/HIV-2

All material of human origin should be considered as potentially infectious and it is recommended that this kit and test specimens be handled using established good laboratory practice.

Pursuant	to	EC	Regulat	ion	1272/2008	(CLP)	hazardous	reagents	are
classified	an	d lal	beled as	foll	ows:				

Reagents:	CONTROL REAGENT	SPECIFIC REAGENT	
Classification:	Skin sens. 1 H317		
Signal Word:	Warning		
Symbols / Pictograms:	(٢)		
Hazard Statements	H317 May cause an allergio	c skin reaction.	
Precautionary Statements:	P280 Wear protective glove protection/face protection. P363 Wash contaminated of P333+P313 If skin irritation medical advice/attention.	clothing before reuse.	
Contains:	Reaction mass of: 5-chloro one [EC no.247-500-7] and one [EC no. 220-239-6] (3:	2-methyl-2H -isothiazol-3-	

See also Murex HBsAg Version 3 (9F80) Instructions for Use.

ANALYTICAL PRECAUTIONS

- See also Murex HBsAg Version 3 (9F80) Instructions for Use. Avoid cross-contamination of controls, samples or other reagents with 1. the Specific Reagent.
- 2. Do not use the reagents beyond the stated expiry date. Microbiological contamination of reagents must be avoided as this may reduce the life of the product and cause erroneous results.
- 3. Do not modify the Test Procedure or substitute reagents from other manufacturers or other lots. Do not reduce any of the recommended incubation times.
- 4. Allow all reagents and samples to come to 18 to 30°C before use. Immediately after use return all reagents to the recommended storage temperature.
- 5. Any glassware to be used with the reagents should be thoroughly washed with 2M hydrochloric acid and then rinsed with distilled water or high quality deionized water.
- 6. Avoid the use of self-defrosting freezers for the storage of reagents and samples.
- 7. Do not expose reagents to strong light or hypochlorite fumes during storage or during incubation steps.
- 8. Do not allow wells to become dry during the assay procedure.
- 9. The possibility of cross contaimation between assays needs to be excluded when validating assay protocols on instrumentation.

SPECIMEN COLLECTION, TRANSPORT AND STORAGE

SPECIMEN COLLECTION

Serum, EDTA plasma or citrate plasma samples may be used. Ensure that the serum samples are fully clotted. Remove any visible particulate matter from the sample by centrifugation.

SPECIMEN TRANSPORT AND STORAGE

Store samples at 2 to 8°C. Samples not required for assay within 72 hours should be removed from the clot or cell pellet and stored frozen (-15°C or colder). Avoid multiple freeze-thaw cycles. After thawing, ensure samples are thoroughly mixed before testing.

PROCEDURE

MATERIALS REQUIRED BUT NOT PROVIDED

- Murex HBsAg Version 3 (9F80).
- 2. Glass or plastic tubes or microplates for diluting samples.
- 3. Micropipettes and Multichannel micropipettes of appropriate volume.
- Physiological Saline (0.85 g NaCl in 100 ml distilled water) for diluting samples.
- Other materials and equipment as for Murex HBsAg Version 3 (9F80). TEST PROCEDURE


Please read 'Analytical Precautions' carefully before performing the test.

Notes:

- Include a minimum of one Negative Control and one Positive Control in each assay run.
- Mix the Control and Specific Reagents thoroughly by inversion prior to use.
- Addition of the various components of the assay to the wells may be confirmed visually by examining the plate for the following colours.
 Control Reagent is yellow and changes to green on addition of the controls or sample, the Positive Control and some plasma samples will produce only a slight change but some difference should always be visible.

Specific Reagent is red and changes to purple on addition of the controls or sample.

- Samples diluted in saline will give little or no colour change with either reagent.
- Samples giving a maximum absorbance reading in Murex HBsAg Version 3 should be diluted 1/100 in 0.85% Saline before use. All other samples can be tested undiluted.
- 5. Two assay wells are used for each sample and control (see Figure 1).



- Step 1 Prepare the Substrate Solution and Wash Fluid. See Murex HBsAg Version 3 (9F80) Instructions for Use.
- Step 2 Use only the number of wells required for the test. Avoid touching the tops or bottoms of the wells.

Step 3	Add 25 µl of Control Reagent into appropriate wells (see Figure 1).	25 µl
Step 4	Add 25 µl of Specific Reagent into appropriate wells (see Figure 1).	25 µl
Step 5	Add 75 µl of Murex HBsAg Controls and Test Samples to the wells (see Figure 1).	75 µl
Step 6	Shake the plate using a plate shaker for 10 seconds. Alternatively the plate may be manually agitated by gently tapping the side for 10 seconds.	10 secs
Step 7	Proceed from and including Step 5 of the Murex	

HBsAg Version 3 (9F80) Test Procedure as described in the Instructions for Use.

RESULTS

Exa

CALCULATION OF RESULTS

When reading the absorbance of each well at 450 nm, a reference wavelength in the range 620 to 690 nm may be used if available ($A_{d=SQ}$ _{REF}). Blank the instrument on air (no plate in carriage).

Each plate must be considered separately when calculating and interpreting results of the assay. Approved software may be used for calculation and interpretation of results.

1. Negative Control

Calculate the mean absorbance of the Negative Control incubated with Specific and Control Reagent.

mpie:		

A _{450/REF} of Negative Control with Specific Reagent (NS)	=	0.080
A450/REF of Negative Control with Control Reagent (NC)	=	0.086
Total	=	0.166
Mean Negative Control = 0.166/2	=	0.083

WHO PQDx PR

2. Cut-off value

This is calculated as the mean absorbance of the Negative Controls +0.05

3. Positive Control

Calculate the percentage inhibition of the Positive Control with Specific Reagent. Example:

$A_{\rm 450/REF}$ of Positive Control with Control Reagent (PC)	= 1.061
$A_{\rm 450/REF}$ of Positive Control with Specific Reagent (PS)	= 0.121
Inhibition by Specific Reagent = [(PC - NC) - (PS - NS)]	x 100
(PC - NC)	
$= [(1.061 - 0.086) - (0.121 - 0.080)] \times 100$	= 95.8%

4. Reactive Samples

Calculate the inhibition of reactive samples. Example:

A_4	so/REF of sample with Control Reagent (SC)	= 0.648			
A_4	A450/REF of sample with Specific Reagent (SS)				
Inh	Inhibition by Specific Reagent = [(SC - NC) - (SS - NS)]				
	(SC - NC)				
=	[(0.648 - 0.086) - (0.099 - 0.080)] x 100	= 96.6%			
	(0.648 - 0.086)				

For samples giving maximum absorbance readings or absorbance readings greater than 2.0 with the Control Reagent, an absorbance value of 2.0 should be used for the calculations.

QUALITY CONTROL

Results of an assay run are valid if the following criteria for the controls are met: Negative Control

The mean A450/BFF is less than 0.15 or the mean A450 is less than 0.2.

HBsAg Positive Control

The $A_{450/\text{REF}}$ or A_{450} of the Positive Control incubated with Control Reagent is more than 0.8 above the mean absorbance of the Negative Control

The absorbance of the Positive Control incubated with Specific Reagent is reduced by at least 80% of the Positive Control incubated with Control Reagent.

Assays which do not meet these criteria should be repeated.

In the unlikely event of the results repeatedly failing to meet either the Quality Control criteria or the expected performance of the test, please contact your representative.

INTERPRETATION OF RESULTS

Confirmed reactive result

For a sample to be considered as confirmed reactive in the Murex HBsAg Version 3 assay (9F80), the following criteria must be met:-

- (i) The absorbance with the Control Reagent must be equal to or greater than the Cut-off value. If the sample has been tested undiluted and does not meet this criterion it should be considered as indeterminate. If the sample is diluted and fails this criterion it should be tested again but undiluted.
- (ii) Inhibition by the Specific Reagent must be equal to or greater than 50%. For strongly reactive samples, if the inhibition is less than 50% and the absorbance with the Control Reagent is greater than 2.0 the sample should be repeated at a dilution of 1/100 or 1/10,000 as appropriate. Percentages may occasionally exceed 100%.

Non-reactive result

Providing the absorbance in the control well is less than 2.0 then samples giving less than 50% inhibition by the Specific Reagent are considered negative and therefore false reactive in Murex HBsAg Version 3 (9F80). A negative percentage inhibition may be encountered and should also be considered as a negative result.

SPECIFIC PERFORMANCE CHARACTERISTICS

A total of 49 samples, which were reactive with at least two immunoassays for the detection of hepatitis B surface antigen, have been tested with Murex HBsAg Confirmatory Version 3 (2G27). The samples included specimens from patients at various stages of hepatitis B infection.

All of the samples were confirmed when tested without dilution in Murex HBsAg Confirmatory Version 3 (2G27).

In addition a total of 238 samples, which were reactive with Murex HBsAg Version 3 (9F80) and at least one other immunoassay for the detection of hepatitis B surface antigen, have been tested with Murex HBsAg Confirmatory Version 3 (2G27). The samples included specimens from patients infected with known subtypes or mutant forms of hepatitis B.

All of the 105 samples which gave a below maximum absorbance reading with Murex HBsAg Version 3 (9F80) were confirmed when tested without further dilution in Murex HBsAg Confirmatory Version 3 (2G27).

Of the remaining 133 samples, which gave maximum absorbance reading with Murex HBsAg Version 3 (9F80), 17 were confirmed with no further dilution 94 were confirmed at a dilution factor of 100 (1/100) and 22 were confirmed at a dilution factor of greater than 100 with Murex HBsAg Confirmatory Version 3 (2G27).

LIMITATIONS OF THE PROCEDURE

See also the Murex HBsAg Version 3 (9F80) Instructions for Use.

- 1. The Test Procedure and Interpretation of Results must be followed. 2. This confirmatory assay discriminates between true and false reactivity
- in Murex HBsAg Version 3 (9F80). This assay has been shown to be effective with mutated forms of HBsAg, however it is possible (as with any neutralisation assay) that some forms of HBsAg may fail to be inhibited. To establish the HBV status of an individual this assay should be used in conjunction with other HBsAg assays and tests for HBV markers, e.g. anti-HBc IgM, anti-HBc, HBe, anti-HBe, HBV DNA.
- This test has only been evaluated for use with individual (unpooled) 3. serum, EDTA plasma or citrate plasma samples.
- 4. Some false positive results occur due to reactivity with animal proteins. The absorbance of these samples will be reduced by both the Control and Specific Reagent. Rarely, the Specific Reagent may have a greater effect than the Control Reagent, which, upon calculation, will appear as confirmation. In this situation, if the absorbance is also markedly decreased by the Control Antibody, the sample is unlikely to be positive and must be tested by another method.
- 5. A negative result with an antigen detection or confirmatory test does not preclude the possibility of infection with HBV.

ProClin@ 300 is not a trade mark of DiaSorin.



DiaSorin S.p.A. UK Branch Central Road, Dartford DA1 5LR



C08DS37GB September, 2014